| Backgroud:Renal cell carcinoma is one of the common cancer in clinical.The most common malignant tumor is bladder cancer,the second is renal cell carcinoma in the urinary surgery in our country.The incedence rate and death rate of RCC in all the human tumor is about 2%.Its high potential of invasion and metastasis leads to a high recurrence/metastasis postoperatively and a very poor prognosis.So the study on mechanism of RCC growth,recurrence/metastasis and the search for bio-markers reflecting recurrence/metastasis and prognosis of RCC patients is valuable in treatment and prognostic counseling.Documents have shown that the invasion and metastasis of malignancies is the key factor releated to the prognosis of patients with cancer.Recently several studies found that Egf17 is a protein to obviously reinfore the ability of cell motility and is shown to be highly expressed both in hepatocellular carcinoma and in other tumor cell lines,which implied that Egf17 may be associated with recurrence/metastasis and prognosis of RCC.It has not been clear whether or not Egf17 is engaged in the process of RCC recurrence/metastasis.Objective:To study on the expression of Egf17 in Renal cell carcinoma(RCC) and the relationship between the expression levels and the clinicopathological parameters of RCC,and to analyze the possible molecular biologic mechanism of the RCC growth and recurrence/ metastasis.We also estimated the value of Egf17 in the RCC prognosis counseling,aiming at providing a novel bio-marker or RCC diagnosis and a new method for RCC treatment.Methods:Forty-six RCC and Fifteen para-cancer renal tissues (PCRT) and Eight normal renal tissues were obtained underwent nephrectomy between January,2000 and August,2004 in the Second Xiangya Hospital of Central South University.Immunonistochemistry was performed for determine the expression of Egf17 protein and its localization in the RCC tissues.To explore the correlation between Egf17 expression levels and the prognosis of RCC patients,follow-up study was applied on the Forty-six patients involved in this research.Results:The result of Immunohistechermial analysis indicate the expression the expression level of Egf17 protein were higher on RCC tissues than that on PCRT(84.8%,P＜0.05) and the expression level on PCRT also higher than that on normal(20.0%,P＜0.05),both with significant difference.Our data also indicated that there is a highly significant correlation of the total Egf17 protein expression levels with clinical degree,tumor diameter,unpeplos and tumor vein invasion(P＜0.05).The result of Immunohistechermical analysis indicate Egf17 protein mainly locates in the endochylema of tumor cells.With the prognosis of 38 cases,11 cases showed death and 7 cases showed metastasis in 5 years. The positive expression of Egf17 was 8 cases and negative expression was 3 cases in the group showed death.In the cases with metastasis,the positive expression of Egf17 was 6 cases and negative expression was 2 cases.It was significantly different in the three groups with Egf17 protein(x~2=7.540 P＜0.05).The positive expression of Egf17 protein in the group with death and metastasis showed higher than those with no death and metastasis.The prognosis of RCC cases with positive expression of Egf17 is lower than those with negative expression.Conclusion:We firstly demonstrated the high expression of Egf17 in RCC tissues and the Egf17 expression levels positively correlate with the clinical degree,tumor diameter,unpeplos and vein invasion significantly. The high expression of Egf17 protein significantly correlates with the recurrence/metastasis of RCC patients.Our results indicate that Egf17 can be of great value in predicting the tumor growth,recurrence/metastasis and poor prognosis of RCC patients and may be a potential target for RCC. |
PDF Full Text Request